Certa Therapeutics' FT011 Granted US FDA Fast Track for the Treatment of Systemic Sclerosis

MELBOURNE, Australia, Feb. 19, 2024 (GLOBE NEWSWIRE) -- Certa Therapeutics (Certa), a biotechnology company developing innovative precision therapies for patients with inflammatory and fibrotic diseases, today announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its investigational therapy FT011 for the treatment of systemic sclerosis (scleroderma), having previously granted Orphan Drug Designation.[1] The Fast Track Designation was granted based on r

Related Keywords

Australia ,Melbourne ,Victoria ,Australian ,Darren Kelly ,Sue Charles ,Kirrily Davis ,Linkedin ,European Medicines Agency ,Australian Therapeutic Goods Agency ,Drug Administration ,Fast Track Designation ,Orphan Drug ,Lacerta Therapeutics ,New Drug Application ,Accessed January ,Non Invasive Surrogates ,Systemic Sclerosis ,Australian Therapeutic Goods ,Orphan Drug Designation ,Fast Track ,Food And Drug Administration ,Cleroderma Patients ,Biotechnology Company ,Certa ,Potential ,Scleroderma ,Track ,Herapeutics ,Ibrosis ,